Showing 1881-1890 of 5631 results for "".
- China Gives Green Light to Allergan’s Xen Registration for the Surgical Management of Refractory Glaucomahttps://modernod.com/news/china-gives-green-light-to-allergans-xen-registration-for-the-surgical-management-of-refractory-glaucoma/2477514/Allergan announced China’s National Medical Products Administration (NMPA) approved the registration of Allergan’s Xen Gel Stent on March 26, 2020 for the surgical management of patients with refractory glaucoma. Xen is th
- Allergan to Present New Data on Investigational Medicines at AAOhttps://modernod.com/news/allergan-to-present-new-data-on-investigational-medicines-at-aao/2479768/Allergan will present new data at the annual meeting of the American College of Ophthalmology (AAO) to be held in Chicago. The Retina Subspecialty Day (October 26-27) will feature two late-breaker presentations on the
- ImprimisRx to Feature New Formulation and Poster Presentation on MKO Melt at AAO Meeting in Chicagohttps://modernod.com/news/imprimisrx-to-feature-new-formulation-and-poster-presentation-on-mko-melt-at-aao-meeting-in-chicago/2479781/ImprimisRx announced its participation at the upcoming 2018 American Academy of Ophthalmology (AAO) annual meeting to be held at the McCormick Place Convention Center in Chicago, October 26-30. At the conference, attendees will have the opportunity to meet with ImprimisRx representatives
- Altris AI Launches Altris Sync App Allowing AI to Directly Sync to OCT Deviceshttps://modernod.com/news/altris-ai-launches-altris-sync-app-allowing-ai-to-directly-sync-to-oct-devices-ai-now-connects-to-oct-devices-from-8-manufacturers-and-enables-analysis-of-historical-data/2482891/Altris AI announces the release of 'Altris Sync,' a secure application that syncs AI directly to OCT devices from 8 OCT manufacturers. The introduction of Altris Sync for automated upload of OCT files is desinged to remove the need for manual operations and bring AI de
- Lighthouse Guild and Bionic Sight Announce Partnership Designed to Expand Treatment Options for People Who Are Blindhttps://modernod.com/news/lighthouse-guild-and-bionic-sight-announce-partnership-designed-to-expand-treatment-options-for-people-who-are-blind/2481264/Lighthouse Guild and Bionic Sight announced that they are entering into a partnership designed to impoved the landscape of treatment for people who are blind. Bionic Sight’s technology focuses on restoring sight to patients with advanced stage blindness due to retinal de
- Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLighthttps://modernod.com/news/lumenis-receives-fda-approval-for-its-ipl-device-to-manage-dry-eye-disease-and-launches-optilight/2479143/Lumenis announced that the FDA has granted De Novo authorization for Lumenis’ newest intense pulsed light (IPL) device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD). The Lumenis multicenter, double-blinded, randomized controlled FDA trial showed that
- Researchers Take Step Closer to Developing AMD Eye Dropshttps://modernod.com/news/researchers-take-step-closer-to-developing-amd-eye-drops/2480007/Scientists at the University of Birmingham, UK, say they are one step closer to developing an eye drop that could revolutionize treatment for age-related macular degeneration (AMD), according to a university news release. Scientists led by biochemist Felicity de Cogan, PhD, from the Univer
- Study: Implandata’s Eyemate System Protects Glaucoma Patients–Even During Lockdownhttps://modernod.com/news/study-implandatas-eyemate-system-protects-glaucoma-patients-even-during-lockdown/2478767/Patients with glaucoma are at high risk of losing their eyesight if their disease progresses undetected and essential therapy adjustments are delayed. On the other hand, these typically elderly, vulnerable individuals are often hampered in seeing their doctor for office visits, particularly durin
- Harrow Announces Availability of Fortisite Formulations for In-Office Usehttps://modernod.com/news/harrow-announces-availability-of-fortisite-formulations-for-in-office-use/2481322/Harrow announced the availability, for in-office use, of Fortisite (compounded Tobramycin 1.5% + Vancomycin 5%) from its FDA‑registered and FDA‑inspected ImprimisRx 503B outsourcing facility. Fortisite formulations are patent-pending high-concentration, refrigeration-stable, f
- Alcon Inaugurates Company’s Largest European Eye Health Education and Training Center in Barcelonahttps://modernod.com/news/alcon-inaugurates-companys-largest-european-eye-health-education-and-training-centre-in-barcelona/2480404/Alcon officially opened the new Alcon Experience Center (AEC) in Barcelona, one of Europe's largest eye health education and training facilities, offering eye care professionals the opportunity to learn and gain hands-on experience with the latest innovations in ophthalmology and optometry. T